FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:CENPC-PAICS

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: CENPC-PAICS
FusionPDB ID: 15690
FusionGDB2.0 ID: 15690
HgeneTgene
Gene symbol

CENPC

PAICS

Gene ID

1060

10606

Gene namecentromere protein Cphosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazolesuccinocarboxamide synthase
SynonymsCENP-C|CENPC1|MIF2|hcp-4ADE2|ADE2H1|AIRC|PAIS
Cytomap

4q13.2

4q12

Type of geneprotein-codingprotein-coding
Descriptioncentromere protein CCENP-C 1centromere autoantigen Ccentromere autoantigen C1centromere protein C 1interphase centromere complex protein 7multifunctional protein ADE2AIR carboxylaseSAICAR synthetasemultifunctional protein ADE2H1phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole succinocarboxamide synthetasephosphoribosylaminoimidazole carboxylase; phosphoribosylamin
Modification date2020032020200313
UniProtAcc

Q03188

Main function of 5'-partner protein: FUNCTION: Component of the CENPA-NAC (nucleosome-associated) complex, a complex that plays a central role in assembly of kinetochore proteins, mitotic progression and chromosome segregation. The CENPA-NAC complex recruits the CENPA-CAD (nucleosome distal) complex and may be involved in incorporation of newly synthesized CENPA into centromeres. CENPC recruits DNA methylation and DNMT3B to both centromeric and pericentromeric satellite repeats and regulates the histone code in these regions. {ECO:0000269|PubMed:19482874, ECO:0000269|PubMed:21529714}.
.
Ensembl transtripts involved in fusion geneENST idsENST00000273853, ENST00000399688, 
ENST00000514888, ENST00000264221, 
ENST00000512576, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score3 X 4 X 3=362 X 2 X 2=8
# samples 42
** MAII scorelog2(4/36*10)=0.15200309344505
effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs).
DoF>8 and MAII>0
log2(2/8*10)=1.32192809488736
Fusion gene context

PubMed: CENPC [Title/Abstract] AND PAICS [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: CENPC [Title/Abstract] AND PAICS [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)CENPC(68405556)-PAICS(57325536), # samples:1
Anticipated loss of major functional domain due to fusion event.CENPC-PAICS seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
CENPC-PAICS seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
CENPC-PAICS seems lost the major protein functional domain in Hgene partner, which is a epigenetic factor due to the frame-shifted ORF.
CENPC-PAICS seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF.
CENPC-PAICS seems lost the major protein functional domain in Tgene partner, which is a cell metabolism gene due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID


check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr4:68405556/chr4:57325536)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across CENPC (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across PAICS (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000273853CENPCchr468405556-ENST00000264221PAICSchr457325536+2479482137550137
ENST00000273853CENPCchr468405556-ENST00000512576PAICSchr457325536+775482137550137

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000273853ENST00000264221CENPCchr468405556-PAICSchr457325536+0.338187370.6618126
ENST00000273853ENST00000512576CENPCchr468405556-PAICSchr457325536+0.0715969350.928403

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for CENPC-PAICS

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
CENPCchr468405556PAICSchr457325536482115KIKDTCIQSPSKEVLAVQPYFLQKDQ

Top

Potential FusionNeoAntigen Information of CENPC-PAICS in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
CENPC-PAICS_68405556_57325536.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
CENPC-PAICSchr468405556chr457325536482HLA-B50:01KEVLAVQP0.97540.93811119
CENPC-PAICSchr468405556chr457325536482HLA-B52:01IQSPSKEV0.95490.9018614
CENPC-PAICSchr468405556chr457325536482HLA-B44:03KEVLAVQPY0.99750.92181120
CENPC-PAICSchr468405556chr457325536482HLA-B47:01KEVLAVQPY0.99660.55341120
CENPC-PAICSchr468405556chr457325536482HLA-B15:01IQSPSKEVL0.99540.6987615
CENPC-PAICSchr468405556chr457325536482HLA-B18:01KEVLAVQPY0.98510.8291120
CENPC-PAICSchr468405556chr457325536482HLA-B14:01IQSPSKEVL0.960.7852615
CENPC-PAICSchr468405556chr457325536482HLA-B14:02IQSPSKEVL0.960.7852615
CENPC-PAICSchr468405556chr457325536482HLA-B39:01IQSPSKEVL0.92830.8888615
CENPC-PAICSchr468405556chr457325536482HLA-B35:04SPSKEVLAV0.890.9616817
CENPC-PAICSchr468405556chr457325536482HLA-B35:02SPSKEVLAV0.890.9616817
CENPC-PAICSchr468405556chr457325536482HLA-B15:03IQSPSKEVL0.86920.6074615
CENPC-PAICSchr468405556chr457325536482HLA-B35:03SPSKEVLAV0.81420.8019817
CENPC-PAICSchr468405556chr457325536482HLA-B15:18IQSPSKEVL0.80920.5427615
CENPC-PAICSchr468405556chr457325536482HLA-B39:13IQSPSKEVL0.74360.9095615
CENPC-PAICSchr468405556chr457325536482HLA-B38:02IQSPSKEVL0.73840.9365615
CENPC-PAICSchr468405556chr457325536482HLA-B38:01IQSPSKEVL0.72960.9226615
CENPC-PAICSchr468405556chr457325536482HLA-B13:02IQSPSKEVL0.65620.5611615
CENPC-PAICSchr468405556chr457325536482HLA-B35:08SPSKEVLAV0.64270.8499817
CENPC-PAICSchr468405556chr457325536482HLA-B35:01SPSKEVLAV0.55220.8027817
CENPC-PAICSchr468405556chr457325536482HLA-B13:01IQSPSKEVL0.53990.9042615
CENPC-PAICSchr468405556chr457325536482HLA-A32:13EVLAVQPYF0.51110.96371221
CENPC-PAICSchr468405556chr457325536482HLA-B35:05SPSKEVLAV0.47450.6754817
CENPC-PAICSchr468405556chr457325536482HLA-B52:01IQSPSKEVL0.11860.8821615
CENPC-PAICSchr468405556chr457325536482HLA-B15:03KEVLAVQPY0.08130.84191120
CENPC-PAICSchr468405556chr457325536482HLA-B44:03KEVLAVQPYF0.99390.86311121
CENPC-PAICSchr468405556chr457325536482HLA-B57:03KEVLAVQPYF0.90920.91421121
CENPC-PAICSchr468405556chr457325536482HLA-B44:03SKEVLAVQPY0.47150.90851020
CENPC-PAICSchr468405556chr457325536482HLA-B48:01TCIQSPSKEVL0.98360.5293415
CENPC-PAICSchr468405556chr457325536482HLA-B13:02IQSPSKEVLAV0.9350.7661617
CENPC-PAICSchr468405556chr457325536482HLA-B40:06KEVLAVQP0.99970.85851119
CENPC-PAICSchr468405556chr457325536482HLA-C01:17QSPSKEVL0.97280.9638715
CENPC-PAICSchr468405556chr457325536482HLA-C01:30QSPSKEVL0.90150.9587715
CENPC-PAICSchr468405556chr457325536482HLA-B39:09IQSPSKEVL0.95430.6994615
CENPC-PAICSchr468405556chr457325536482HLA-C02:06IQSPSKEVL0.9320.9428615
CENPC-PAICSchr468405556chr457325536482HLA-B15:04IQSPSKEVL0.93020.7148615
CENPC-PAICSchr468405556chr457325536482HLA-B39:08IQSPSKEVL0.92380.8194615
CENPC-PAICSchr468405556chr457325536482HLA-B15:31EVLAVQPYF0.91720.65361221
CENPC-PAICSchr468405556chr457325536482HLA-C08:04IQSPSKEVL0.90280.948615
CENPC-PAICSchr468405556chr457325536482HLA-C08:13IQSPSKEVL0.90280.948615
CENPC-PAICSchr468405556chr457325536482HLA-C07:13IQSPSKEVL0.90230.9208615
CENPC-PAICSchr468405556chr457325536482HLA-B78:01SPSKEVLAV0.89810.5396817
CENPC-PAICSchr468405556chr457325536482HLA-B39:12IQSPSKEVL0.89250.8913615
CENPC-PAICSchr468405556chr457325536482HLA-B35:12SPSKEVLAV0.890.9616817
CENPC-PAICSchr468405556chr457325536482HLA-C08:03IQSPSKEVL0.88130.9787615
CENPC-PAICSchr468405556chr457325536482HLA-C07:29IQSPSKEVL0.86440.8902615
CENPC-PAICSchr468405556chr457325536482HLA-B51:07SPSKEVLAV0.80390.9343817
CENPC-PAICSchr468405556chr457325536482HLA-B14:03IQSPSKEVL0.79930.8128615
CENPC-PAICSchr468405556chr457325536482HLA-B14:03SPSKEVLAV0.77110.8841817
CENPC-PAICSchr468405556chr457325536482HLA-B39:05IQSPSKEVL0.69640.8729615
CENPC-PAICSchr468405556chr457325536482HLA-B39:10SPSKEVLAV0.33220.9115817
CENPC-PAICSchr468405556chr457325536482HLA-B15:05IQSPSKEVL0.23850.737615
CENPC-PAICSchr468405556chr457325536482HLA-C01:03QSPSKEVL0.99950.9601715
CENPC-PAICSchr468405556chr457325536482HLA-C01:02QSPSKEVL0.99050.9624715
CENPC-PAICSchr468405556chr457325536482HLA-B50:04KEVLAVQP0.97540.93811119
CENPC-PAICSchr468405556chr457325536482HLA-B50:05KEVLAVQP0.97540.93811119
CENPC-PAICSchr468405556chr457325536482HLA-B44:13KEVLAVQPY0.99750.92181120
CENPC-PAICSchr468405556chr457325536482HLA-B44:26KEVLAVQPY0.99750.92181120
CENPC-PAICSchr468405556chr457325536482HLA-B44:07KEVLAVQPY0.99750.92181120
CENPC-PAICSchr468405556chr457325536482HLA-B15:24IQSPSKEVL0.9960.7576615
CENPC-PAICSchr468405556chr457325536482HLA-B15:33IQSPSKEVL0.99540.6987615
CENPC-PAICSchr468405556chr457325536482HLA-B15:34IQSPSKEVL0.99540.6987615
CENPC-PAICSchr468405556chr457325536482HLA-B15:125IQSPSKEVL0.99540.6987615
CENPC-PAICSchr468405556chr457325536482HLA-B15:135IQSPSKEVL0.99520.6985615
CENPC-PAICSchr468405556chr457325536482HLA-B15:27IQSPSKEVL0.99510.7563615
CENPC-PAICSchr468405556chr457325536482HLA-B15:50IQSPSKEVL0.99230.8254615
CENPC-PAICSchr468405556chr457325536482HLA-A25:01EVLAVQPYF0.99060.73841221
CENPC-PAICSchr468405556chr457325536482HLA-B18:08KEVLAVQPY0.98840.87811120
CENPC-PAICSchr468405556chr457325536482HLA-B18:07KEVLAVQPY0.98770.78611120
CENPC-PAICSchr468405556chr457325536482HLA-B18:04KEVLAVQPY0.98670.84131120
CENPC-PAICSchr468405556chr457325536482HLA-B18:05KEVLAVQPY0.98510.8291120
CENPC-PAICSchr468405556chr457325536482HLA-B18:06KEVLAVQPY0.9840.83911120
CENPC-PAICSchr468405556chr457325536482HLA-B18:03KEVLAVQPY0.9790.81421120
CENPC-PAICSchr468405556chr457325536482HLA-B15:73IQSPSKEVL0.97140.7926615
CENPC-PAICSchr468405556chr457325536482HLA-C03:67IQSPSKEVL0.97090.9425615
CENPC-PAICSchr468405556chr457325536482HLA-B15:53IQSPSKEVL0.96820.6548615
CENPC-PAICSchr468405556chr457325536482HLA-B18:11KEVLAVQPY0.96110.71041120
CENPC-PAICSchr468405556chr457325536482HLA-B15:30IQSPSKEVL0.94550.6906615
CENPC-PAICSchr468405556chr457325536482HLA-B39:31IQSPSKEVL0.93620.8886615
CENPC-PAICSchr468405556chr457325536482HLA-B39:02IQSPSKEVL0.92690.911615
CENPC-PAICSchr468405556chr457325536482HLA-B35:20EVLAVQPYF0.91570.71141221
CENPC-PAICSchr468405556chr457325536482HLA-C07:04IQSPSKEVL0.90460.8901615
CENPC-PAICSchr468405556chr457325536482HLA-B35:09SPSKEVLAV0.890.9616817
CENPC-PAICSchr468405556chr457325536482HLA-B15:12IQSPSKEVL0.88630.7715615
CENPC-PAICSchr468405556chr457325536482HLA-B39:11IQSPSKEVL0.8820.814615
CENPC-PAICSchr468405556chr457325536482HLA-C08:01IQSPSKEVL0.88130.9787615
CENPC-PAICSchr468405556chr457325536482HLA-B15:13EVLAVQPYF0.87780.65511221
CENPC-PAICSchr468405556chr457325536482HLA-B15:54IQSPSKEVL0.87530.6208615
CENPC-PAICSchr468405556chr457325536482HLA-B78:02SPSKEVLAV0.85470.6459817
CENPC-PAICSchr468405556chr457325536482HLA-B35:13SPSKEVLAV0.83170.8049817
CENPC-PAICSchr468405556chr457325536482HLA-B15:20KEVLAVQPY0.75880.84191120
CENPC-PAICSchr468405556chr457325536482HLA-B15:12KEVLAVQPY0.75760.90291120
CENPC-PAICSchr468405556chr457325536482HLA-B38:05IQSPSKEVL0.72960.9226615
CENPC-PAICSchr468405556chr457325536482HLA-B35:28KEVLAVQPY0.69330.85121120
CENPC-PAICSchr468405556chr457325536482HLA-B48:02IQSPSKEVL0.67620.81615
CENPC-PAICSchr468405556chr457325536482HLA-B08:12SPSKEVLAV0.6230.5261817
CENPC-PAICSchr468405556chr457325536482HLA-B35:20KEVLAVQPY0.61780.86651120
CENPC-PAICSchr468405556chr457325536482HLA-B15:53KEVLAVQPY0.57760.90021120
CENPC-PAICSchr468405556chr457325536482HLA-B35:23SPSKEVLAV0.5760.8038817
CENPC-PAICSchr468405556chr457325536482HLA-B35:77SPSKEVLAV0.55220.8027817
CENPC-PAICSchr468405556chr457325536482HLA-B67:01SPSKEVLAV0.54530.796817
CENPC-PAICSchr468405556chr457325536482HLA-B15:09IQSPSKEVL0.52630.6468615
CENPC-PAICSchr468405556chr457325536482HLA-B07:13IQSPSKEVL0.51920.8083615
CENPC-PAICSchr468405556chr457325536482HLA-B35:13IQSPSKEVL0.48570.8036615
CENPC-PAICSchr468405556chr457325536482HLA-B35:30SPSKEVLAV0.46870.7634817
CENPC-PAICSchr468405556chr457325536482HLA-B35:17SPSKEVLAV0.46870.7634817
CENPC-PAICSchr468405556chr457325536482HLA-B35:28IQSPSKEVL0.23330.8429615
CENPC-PAICSchr468405556chr457325536482HLA-B15:20IQSPSKEVL0.22220.8328615
CENPC-PAICSchr468405556chr457325536482HLA-B15:54KEVLAVQPY0.19130.88761120
CENPC-PAICSchr468405556chr457325536482HLA-B48:02KEVLAVQPY0.12150.82541120
CENPC-PAICSchr468405556chr457325536482HLA-B15:68KEVLAVQPY0.0280.65041120
CENPC-PAICSchr468405556chr457325536482HLA-B44:07KEVLAVQPYF0.99390.86311121
CENPC-PAICSchr468405556chr457325536482HLA-B44:26KEVLAVQPYF0.99390.86311121
CENPC-PAICSchr468405556chr457325536482HLA-B44:13KEVLAVQPYF0.99390.86311121
CENPC-PAICSchr468405556chr457325536482HLA-A69:01EVLAVQPYFL0.97550.51661222
CENPC-PAICSchr468405556chr457325536482HLA-A32:01KEVLAVQPYF0.89650.85991121
CENPC-PAICSchr468405556chr457325536482HLA-B18:11SKEVLAVQPY0.69660.70741020
CENPC-PAICSchr468405556chr457325536482HLA-B44:07SKEVLAVQPY0.47150.90851020
CENPC-PAICSchr468405556chr457325536482HLA-B44:26SKEVLAVQPY0.47150.90851020
CENPC-PAICSchr468405556chr457325536482HLA-B44:13SKEVLAVQPY0.47150.90851020

Top

Potential FusionNeoAntigen Information of CENPC-PAICS in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
CENPC-PAICS_68405556_57325536.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
CENPC-PAICSchr468405556chr457325536482DRB1-0102SKEVLAVQPYFLQKD1025
CENPC-PAICSchr468405556chr457325536482DRB1-0123SKEVLAVQPYFLQKD1025

Top

Fusion breakpoint peptide structures of CENPC-PAICS

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
3928IQSPSKEVLAVQPYCENPCPAICSchr468405556chr457325536482

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of CENPC-PAICS

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN3928IQSPSKEVLAVQPY-7.15543-7.26883
HLA-B14:023BVN3928IQSPSKEVLAVQPY-4.77435-5.80965
HLA-B52:013W393928IQSPSKEVLAVQPY-6.80875-6.92215
HLA-B52:013W393928IQSPSKEVLAVQPY-4.20386-5.23916
HLA-A11:014UQ23928IQSPSKEVLAVQPY-7.5194-8.5547
HLA-A11:014UQ23928IQSPSKEVLAVQPY-6.9601-7.0735
HLA-A24:025HGA3928IQSPSKEVLAVQPY-7.52403-7.63743
HLA-A24:025HGA3928IQSPSKEVLAVQPY-5.82433-6.85963
HLA-B27:056PYJ3928IQSPSKEVLAVQPY-3.28285-4.31815
HLA-B44:053DX83928IQSPSKEVLAVQPY-5.91172-6.94702
HLA-B44:053DX83928IQSPSKEVLAVQPY-4.24346-4.35686

Top

Vaccine Design for the FusionNeoAntigens of CENPC-PAICS

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
CENPC-PAICSchr468405556chr4573255361020SKEVLAVQPYAGCAAAGAGGTCTTGGCTGTTCAACCGTAC
CENPC-PAICSchr468405556chr4573255361119KEVLAVQPAAAGAGGTCTTGGCTGTTCAACCG
CENPC-PAICSchr468405556chr4573255361120KEVLAVQPYAAAGAGGTCTTGGCTGTTCAACCGTAC
CENPC-PAICSchr468405556chr4573255361121KEVLAVQPYFAAAGAGGTCTTGGCTGTTCAACCGTACTTT
CENPC-PAICSchr468405556chr4573255361221EVLAVQPYFGAGGTCTTGGCTGTTCAACCGTACTTT
CENPC-PAICSchr468405556chr4573255361222EVLAVQPYFLGAGGTCTTGGCTGTTCAACCGTACTTTCTC
CENPC-PAICSchr468405556chr457325536415TCIQSPSKEVLACTTGTATTCAGTCACCAAGCAAAGAGGTCTTG
CENPC-PAICSchr468405556chr457325536614IQSPSKEVATTCAGTCACCAAGCAAAGAGGTC
CENPC-PAICSchr468405556chr457325536615IQSPSKEVLATTCAGTCACCAAGCAAAGAGGTCTTG
CENPC-PAICSchr468405556chr457325536617IQSPSKEVLAVATTCAGTCACCAAGCAAAGAGGTCTTGGCTGTT
CENPC-PAICSchr468405556chr457325536715QSPSKEVLCAGTCACCAAGCAAAGAGGTCTTG
CENPC-PAICSchr468405556chr457325536817SPSKEVLAVTCACCAAGCAAAGAGGTCTTGGCTGTT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
CENPC-PAICSchr468405556chr4573255361025SKEVLAVQPYFLQKDAGCAAAGAGGTCTTGGCTGTTCAACCGTACTTTCTCCAGAAGGAT

Top

Information of the samples that have these potential fusion neoantigens of CENPC-PAICS

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
N/ACENPC-PAICSchr468405556ENST00000273853chr457325536ENST00000264221DC389672

Top

Potential target of CAR-T therapy development for CENPC-PAICS

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to CENPC-PAICS

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to CENPC-PAICS

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource